The 20 Best Familial Wilms Tumor 2 Doctors Near Me in Ann Arbor, MI

Ajjai Alva is an Oncologist practicing medicine in Ann Arbor, Michigan. Dr. Alva is rated as a Distinguished provider by MediFind in the treatment of Familial Wilms Tumor 2. He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Urothelial Cancer, Renal Cell Carcinoma (RCC), Bladder Cancer, Nephrectomy, and Lymphadenectomy.

Dr. Vaishampayan is the Director of the Phase I program at the Rogel Cancer Center, University of Michigan, Ann Arbor MI. Dr. Vaishampayan is a Professor of Internal Medicine and her research is primarily in translational drug development and early phase clinical trials in cancer with a focus on genitourinary malignancies. She has initiated, obtained funding for, and conducted and published many investigator initiated trials with embedded biomarkers and established multidisciplinary collaboration. She has served as site PI of the UO-1 Early Therapeutics Research Grant at Wayne State University. She was also the chair of the solid tumor division of oncology at WSU. She has completed formal leadership traning course and is Fellow of the Advisory Board (FAB). She is the appointed chair of the Advanced Renal committee of SWOG and a member of the Renal task force of the NCI. She is a board member of the Michigan Society of Hematology/Oncology (MSHO) and organizes annual board review course. Additionally, she has served as track leader for the ASCO education committee GU non prostate (Renal and bladder cancer) track. Dr. Vaishampayan attended Wayne State University for her residency and fellowship completion and attended medical school at Byramjee Jeejeebhoy in Pune, India and completed a higher secondary certificate in the field of science at Fergusson College in Pune, India.In her free time, Dr. Vaishampayan enjoys reading, dance, music and travel. Travel, reading (mysteries preferred), follows football. Dr. Vaishampayan is rated as a Distinguished provider by MediFind in the treatment of Familial Wilms Tumor 2. She is also highly rated in 36 other conditions, according to our data. Her clinical expertise encompasses Renal Cell Carcinoma (RCC), Prostate Cancer, Urothelial Cancer, Nephrectomy, and Orchiectomy. Dr. Vaishampayan is board certified in Medical Oncology.

Simpa S. Salami, M.D., M.P.H. is a fellowship-trained, board-certified Urologic Oncologist and Associate Professor of Urology at the University of Michigan. He obtained his medical degree from the College of Medicine, University of Ibadan, Nigeria. Thereafter, he completed a Master of Public Health program at Harvard University, General Surgery Internship at the Brigham and Women’s Hospital in Boston, Urology Residency at Hofstra Northwell Health School of Medicine in New York, and Urologic Oncology Fellowship at the University of Michigan in Ann Arbor, Michigan. Dr. Salami’s clinical expertise is in the minimally invasive surgical treatment of prostate and kidney cancer. As a translational surgeon-scientist, his laboratory focuses on developing novel cancer biomarkers to overcome tumor heterogeneity and multifocality as well as elucidate optimal paradigms for early detection of urologic cancers, risk stratification, prognostication, and prediction of treatment response. Dr. Salami’s lab collaborates with investigators all over the world to understand the molecular underpinnings of urologic cancer and associated disparities. Dr. Salami is a recipient of several awards including the: Harvard University Presidential Scholar, Prostate Cancer Foundation Young Investigator, American Urological Association (AUA) Urology Care Foundation (UCF) Research Scholar, AUA UCF Rising Stars in Urologic Research, Harold Amos Medical Faculty Development Fellowship, Rogel Cancer Center Scholar, Society of Urologic Oncology Young Investigator, NCI R37 MERIT and 2024 AUA Gold Cystoscope Awards. Most recently, he was named an inaugural Biden White House Cancer Moonshot Scholar. He has served on several National guideline committees, such as the AUA Prostate Cancer Early Detection Guidelines, the NCCN Prostate Cancer Early Detection Guidelines, and the Society of Nuclear Medicine and Imaging PSMA PET Appropriate Use Criteria Working Group. His research is supported by multiple sources and includes funding from the Department of Defense, National Cancer Institute, and the Prostate Cancer Foundation. Dr. Salami is rated as a Distinguished provider by MediFind in the treatment of Familial Wilms Tumor 2. He is also highly rated in 11 other conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Renal Cell Carcinoma (RCC), Familial Prostate Cancer, Nephrectomy, and Prostatectomy. Dr. Salami is board certified in Urology.

Khaled Hafez is a Urologist practicing medicine in Ann Arbor, Michigan. Dr. Hafez is rated as a Distinguished provider by MediFind in the treatment of Familial Wilms Tumor 2. He is also highly rated in 30 other conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Renal Cell Carcinoma (RCC), Muscle Invasive Bladder Cancer, Nephrectomy, and Cystectomy. Dr. Hafez is board certified in Urology.

Ganesh S. Palapattu, MD, FACS is The George F. and Sandy G. Valassis Professor and Chair of the Department of Urology. He joined the University of Michigan Department of Urology as Associate Professor and Chief of Urologic Oncology in the Fall of 2012. Prior to this he was the Chief of Urologic Oncology at Houston Methodist Hospital in Houston, Texas. Dr. Palapattu has held faculty appointments at the University of Rochester School of Medicine in Rochester, NY where he was also Assistant Residency Program Director and Weill Cornell Medical College/The Houston Methodist Hospital.Dr. Palapattu was born in Toronto, Canada where he developed a passion for street hockey. At the age of 9, his family moved to Houston, Texas where he picked up playing the French horn. Dr. Palapattu graduated from the University of Texas at Austin with a B.A. degree in the Humanities and subsequently attended Baylor College of Medicine. Dr. Palapattu received his surgical/urological training at the David Geffen School of Medicine at UCLA and further specialty training in urologic oncology at Johns Hopkins. He and his wife, Anu, whom he met at UT Austin, have 2 young children. The Palapattu family is enthusiastic about taking advantage of the many outdoor activities the Ann Arbor area affords.When not working, Dr. Palapattu enjoys spending time with his family, traveling and playing/watching sports. Go Blue!. Dr. Palapattu is rated as an Advanced provider by MediFind in the treatment of Familial Wilms Tumor 2. He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Renal Cell Carcinoma (RCC), Familial Prostate Cancer, Nephrectomy, and Prostatectomy. Dr. Palapattu is board certified in Urology.

Todd M. Morgan, M.D. is a urological surgeon specializing in the treatment of genitourinary malignancies. Dr. Morgan is originally from Seattle, WA, and completed his undergraduate and medical training at Harvard University. He returned to the Northwest in 2003 for his urology residency at the University of Washington, before moving to Nashville for his fellowship training in urological oncology at Vanderbilt University. Dr. Morgan is a translational surgeon-scientist, and his research spans the spectrum from preclinical laboratory-based research to prospective clinical trials. The primary focus of his laboratory is on identifying key pathways that predict response and resistance to treatment in genitourinary malignancies. This includes work in prostate cancer to develop liquid biopsy approaches that can guide precision-based therapeutic strategies in real time, as well as ongoing research in renal cell carcinoma to identify genomic signatures for risk stratification.Dr. Morgan is currently an Associate Professor of Urology and has been at the University of Michigan since 2012. In addition to his research pursuits, he is a busy clinician and surgeon offering advanced robotic, laparoscopic, and open surgical approaches for patients with genitourinary malignancies. He has substantial expertise in the use and interpretation of molecular biomarkers, which can help guide individualized treatment choice for some patients.Beyond work, he loves his time enjoying the great town of Ann Arbor and beautiful state of Michigan with his wife, Wendy, and their two young boys. Whether camping in Petoskey, sitting on a beach in Grand Haven, or biking around the neighborhood in Ann Arbor, the Morgan family has quickly learned that life in the Midwest is hard to beat. Dr. Morgan is rated as an Advanced provider by MediFind in the treatment of Familial Wilms Tumor 2. He is also highly rated in 20 other conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Muscle Invasive Bladder Cancer, Bladder Cancer, Prostatectomy, and Nephrectomy. Dr. Morgan is board certified in Urology.

Alice Semerjian is a Urologist practicing medicine in Ann Arbor, Michigan. Dr. Semerjian is rated as an Advanced provider by MediFind in the treatment of Familial Wilms Tumor 2. She is also highly rated in 22 other conditions, according to our data. Her clinical expertise encompasses Renal Cell Carcinoma (RCC), Bladder Cancer, Urothelial Cancer, Nephrectomy, and Reconstructive Urology Surgery. Dr. Semerjian is board certified in Urology.

Lindsey Herrel is a Urologist practicing medicine in Ann Arbor, Michigan. Dr. Herrel is rated as an Advanced provider by MediFind in the treatment of Familial Wilms Tumor 2. She is also highly rated in 18 other conditions, according to our data. Her clinical expertise encompasses Prostate Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Vasectomy, and Nephrectomy. Dr. Herrel is board certified in Urology.

After graduating from the University of Leeds, Dr. Ghani completed basic surgical training in Edinburgh followed by urological surgery training in London. He was awarded a Master of Surgery thesis from the University of London for research on percutaneous renal stone surgery. Following completion of sub-specialist training in Endourology at the Stone Unit at Guy’s Hospital, London, Dr. Ghani was awarded The Urology Foundation Scholarship and undertook fellowship training in robotic surgery at the Vattikuti Urology Institute, Henry Ford Hospital, Detroit.He joined the University of Michigan in 2013 and leads the Endourology program at the Ann Arbor VA Healthcare System. He treats patients with kidney problems: stones, cancer and obstruction. Dr Ghani has authored over 200 peer-reviewed articles, and his research focuses on endoscopic stone surgery and quality improvement. Specifically, he has been advancing a Dusting technique for ureteroscopy and has extramural funding to study laser lithotripsy in the laboratory. He is the Course Director of the annual Developments in Ureteroscopic Stone Treatment (D.U.S.T.) symposium, an international meeting that has exposed hundreds of urologists to advanced ureteroscopy techniques. He is also the Course Director of the American Urological Association annual course, Dust or Bust.In addition, Dr Ghani serves as the Director of the Michigan Urological Surgery Improvement Collaborative (MUSIC), which is a consortium of 46 urology practices aiming to improve the quality of care for patients with prostate cancer, kidney stones, and kidney cancer. Within MUSIC, he is the principal investigator of two randomized clinical trials assessing patient health-related quality of life and healthcare use after ureteroscopy. Dr. Ghani has received numerous prizes for his presentations and research from the American Urological Association, Endourological Society, European Association of Urology, and has lectured and taught surgeons throughout the world. He is an Assistant Editor for the Journal of Urology and serves on the editorial board of Nature Reviews Urology. Dr. Ghani is rated as an Advanced provider by MediFind in the treatment of Familial Wilms Tumor 2. He is also highly rated in 31 other conditions, according to our data. His clinical expertise encompasses Kidney Stones, Urinary Tract Infection (UTI), Prostate Cancer, Lithotripsy, and Ureteroscopy.

Megan Caram is a Hematologist and an Oncologist practicing medicine in Ann Arbor, Michigan. Dr. Caram is rated as an Advanced provider by MediFind in the treatment of Familial Wilms Tumor 2. She is also highly rated in 8 other conditions, according to our data. Her clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Chromophobe Renal Cell Carcinoma, and Clear Cell Sarcoma. Dr. Caram is board certified in Medical Oncology.

Rama Rao is a Pediatrics provider practicing medicine in Ann Arbor, Michigan. Dr. Rao is rated as an Experienced provider by MediFind in the treatment of Familial Wilms Tumor 2. She is also highly rated in 36 other conditions, according to our data. Her clinical expertise encompasses Osteosarcoma, Chondrosarcoma, Hereditary Neuroblastoma, Neuroblastoma, and Bone Marrow Aspiration. Dr. Rao is board certified in Pediatric Hematology-Oncology.

Bruce Redman is an Oncologist practicing medicine in Ann Arbor, Michigan. Dr. Redman is rated as an Advanced provider by MediFind in the treatment of Familial Wilms Tumor 2. He is also highly rated in 10 other conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, and Wilms Tumor.

The T-cell lymphomas are a heterogeneous and poorly understood group of non-Hodgkin’s lymphomas. The most common T-cell lymphoma in the United States includes a heterogeneous mix of lymphomas that lack distinguishing characteristics and, until recently, remained clinically and molecularly “unspecified”. Improved understanding of T-cell lymphoma pathogenesis and the development of novel therapeutic strategies will be needed to address this challenge and improve outcomes for patients afflicted with these aggressive lymphomas. My group made the landmark discovery that the most common T-cell lymphoma in North America is comprised of two molecularly and clinically distinct subsets. This finding has significant implications for the classification and treatment of these lymphomas. We have also demonstrated that malignant T cells remain dependent upon antigen-presenting cells within the tumor microenvironment and are developing novel therapeutic strategies targeting these cells. Many fundamental questions, including the “cell of origin”, the role of antigen-, costimulatory-, and cytokine-receptor signaling, and the contribution of myeloid-derived antigen-presenting cells in disease pathogenesis remain obscure. My laboratory uses complementary mouse models and primary T-cell lymphoma specimens (in ex vivo and patient-derived xenograft studies) to address these fundamental and clinically relevant questions. We are poised to clinically translate our laboratory-based findings into novel therapeutic strategies that we hope will improve outcomes for patients afflicted with these aggressive lymphomas. I enjoy working with a multidisciplinary team of enthusiastic collaborators who share this common goal. Dr. Wilcox is rated as an Experienced provider by MediFind in the treatment of Familial Wilms Tumor 2. He is also highly rated in 23 other conditions, according to our data. His clinical expertise encompasses T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Peripheral T-Cell Lymphoma, Non-Hodgkin Lymphoma, and Bone Marrow Aspiration. Dr. Wilcox is board certified in Internal Medicine, Hematology, and Medical Oncology.

Joshua Kaplan is a Urologist practicing medicine in Ann Arbor, Michigan. Dr. Kaplan is rated as an Experienced provider by MediFind in the treatment of Familial Wilms Tumor 2. He is also highly rated in 20 other conditions, according to our data. His clinical expertise encompasses Familial Prostate Cancer, Prostate Cancer, Obstructive Uropathy, Ureteroscopy, and Reconstructive Urology Surgery. Dr. Kaplan is board certified in Urology.

Irene Tsung is an Oncologist and an Internal Medicine provider practicing medicine in Ann Arbor, Michigan. She has been practicing medicine for over 10 years. Dr. Tsung is rated as an Experienced provider by MediFind in the treatment of Familial Wilms Tumor 2. She is also highly rated in 1 other condition, according to our data. Her clinical expertise encompasses Prostate Cancer, Urothelial Cancer, Renal Cell Carcinoma (RCC), and WT1-Related Wilms Tumor Syndromes.

Dr. David Smith is a Professor of Internal Medicine and Urology at the University of Michigan and currently serves as the Associate Chief Clinical Officer for Cancer at Michigan Medicine and the Chief Medical Officer of the Rogel Cancer Center. Throughout his career he has focused on caring for patients with urologic cancers, cancer clinical trials, and the delivery of cancer care. Dr. Smith is rated as an Experienced provider by MediFind in the treatment of Familial Wilms Tumor 2. He is also highly rated in 16 other conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Testicular Cancer, Familial Prostate Cancer, Orchiectomy, and Prostatectomy.

Kristian Stensland is a Urologist practicing medicine in Ann Arbor, Michigan. Dr. Stensland is rated as an Experienced provider by MediFind in the treatment of Familial Wilms Tumor 2. He is also highly rated in 6 other conditions, according to our data. His clinical expertise encompasses Lichen Sclerosus, Prostate Cancer, Urethral Stricture, Cystectomy, and Prostatectomy. Dr. Stensland is board certified in Urology.

I ride both a road bike and Peleton. I golf about 2-3 times per week. Have four grandchildren to dote on. I mostly fiction novels. Exercise twice per week. Dr. Terebelo is rated as an Experienced provider by MediFind in the treatment of Familial Wilms Tumor 2. He is also highly rated in 62 other conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Essential Thrombocythemia, Familial Colorectal Cancer, Bone Marrow Aspiration, and Tissue Biopsy.

Dr. Palmbos received his bachelor’s degree from Calvin College in Grand Rapids, Michigan where he graduated with honors in 2000. He completed his combined M.D. and Ph.D. degrees as part of a NIH sponsored medical scientist training program at the University of Michigan Medical School in Ann Arbor, Michigan in 2008. His graduate work focused on the nonhomologous endjoining pathway of DNA double strand break repair. He then completed his Internal Medicine Residency and Hematology/Oncology Fellowship at the University of Michigan in 2010 and 2014 respectively. His clinical interest is genitourinary malignancies and he primarily sees patients with bladder and prostate cancers. His laboratory research focus is on bladder cancer and he is currently developing new preclinical models of bladder cancer and focusing on the role of a novel oncogene, ATDC, in bladder tumor development. He recently received American Society of Clinical Oncology (ASCO) Young Investigator and Bladder Cancer Advocacy Network (BCAN) Young Investigator awards and has an NIH K08 award to develop his research program. Dr. Palmbos is rated as an Experienced provider by MediFind in the treatment of Familial Wilms Tumor 2. He is also highly rated in 6 other conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Prostate Cancer, Familial Prostate Cancer, and Urothelial Cancer. Dr. Palmbos is board certified in Internal Medicine and Medical Oncology.

Bryan J. Schneider, MD is a Professor of Internal Medicine in the Division of Hematology/ Oncology at the University of Michigan, Ann Arbor, Michigan, and is the Section Head for the medical thoracic oncology team who treats lung cancer, esophageal cancer, mesothelioma, thymoma and carcinoid tumors.Dr. Schneider earned his medical degree from Indiana University in 1998. He also completed an internship and residency in internal medicine at the Indiana University School of Medicine and served as Chief Resident in 2001. He completed a fellowship in hematology/oncology at the University of Michigan. He joined the faculty at the University of Michigan as an Assistant Professor in 2005 and was an Assistant Professor at Cornell University in New York City from 2008 to 2014. He returned to the University of Michigan in 2015.Dr. Schneider is a member of the American Society of Clinical Oncology and the International Association for the Study of Lung Cancer. He has served as a member of the Experimental Therapeutics Study Section of the National Institutes of Health and serves on numerous other scientific medical committees. These include the ASCO thoracic guideline advisory group, and the steering committee for the National Cancer Center Network (NCCN) guidelines.Dr. Schneider has published extensively in peer-reviewed journals and has written several book chapters on the subject of lung cancer. He is married with twin boys and a cat. Dr. Schneider is rated as an Experienced provider by MediFind in the treatment of Familial Wilms Tumor 2. He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, and Tissue Biopsy. Dr. Schneider is board certified in Medical Oncology.